Key result
Male sex in preterm infants shows no difference in PDA risk versus female sex.
Why the study?
Whether the male disadvantage of prematurity involves persistent PDA and differences in response to pharmacological treatment had been scarcely investigated.
Does male sex affect the incidence of patent ductus arteriosus or response to pharmacological treatment in preterm infants compared to female sex?
Meta-Analysis (n=357,781)
Yes
Does male sex affect the incidence of patent ductus arteriosus or response to pharmacological treatment in preterm infants compared to female sex?
This meta-analysis demonstrates that unlike other complications of prematurity, there is no 'male disadvantage' in the incidence of PDA or its response to pharmacological treatment in preterm infants.
Answers are grounded in this paper and cite their sources.
No sex difference in PDA risk or treatment response in preterm infants; challenges the male disadvantage seen in other prematurity complications.
A widely accepted concept in perinatal medicine is that boys are more susceptible than girls to complications of prematurity. However, whether this 'male disadvantage of prematurity' also involves persistent patent ductus arteriosus (PDA) has been scarcely investigated. Our aim was to conduct a systematic review and meta-analysis on studies addressing sex differences in the risk of developing PDA among preterm infants. We also investigated whether the response to pharmacological treatment of PDA differs between boys and girls. PubMed/Medline and Embase databases were searched. The random-effects male/female risk ratio (RR) and 95% confidence interval (CI) were calculated. We included 146 studies (357,781 infants). Meta-analysis could not demonstrate sex differences in risk of developing any PDA (37 studies, RR 1.03, 95% CI 0.97 to 1.08), hemodynamically significant PDA (81 studies, RR 1.00, 95% CI 0.97 to 1.02), or in the rate of response to pharmacological treatment (45 studies, RR 1.01, 95% CI 0.98 to 1.04). Subgroup analysis and meta-regression showed that the absence of sex differences was maintained over the years and in different geographic settings. In conclusion, both the incidence of PDA in preterm infants and the response rate to pharmacological treatment of PDA are not different between preterm boys and girls.
No takes yet. Share an insight, caveat, or question.
Borges-Luján et al. (2022) conducted a meta-analysis in Patent ductus arteriosus (n=357,781). Male sex vs. Female sex was evaluated on Risk of developing any patent ductus arteriosus (RR 1.03, 95% CI 0.97-1.08). Male sex in preterm infants was not associated with a different risk of developing any patent ductus arteriosus compared to female sex.
Synapse has enriched 10 related papers. Consider them for comparative context: